bg-country-switch
Key figures

The HARTMANN GROUP, an internationally leading medical device company.

HARTMANN at a glance

We have offices in over 35 countries around the world, but our products are available in around 100 countries through a network of distributors.

HARTMANN is a leading international manufacturer of medical and hygiene products.

In a world where health is becoming an increasingly important matter and is managed more professionally, we offer our customers simple and effective solutions for the benefit of the patients. This is expressed in our brand promise of “Going further for health”. Professional solutions for wound treatment, incontinence hygiene and infection prevention form the core of our portfolio.

In 2018, we employed 11,027 staff worldwide and generated sales of EUR 2,119 million.

The HARTMANN solutions

In line with internal management, the HARTMANN GROUP's business activities are reported on by business segments which are arranged by product range focus, i.e. Wound, Incontinence and Infection Management as well as Other Group Activities, primarily including the activities of the Group companies, KNEIPP, KOB, CMC and NOGE.

Within the Incontinence Management segment, sales increased by 4.3% to €693.7 million. The incontinence brand LINDOR, acquired in 2017, contributed to this growth thanks to its strength in the Spanish and Portuguese market. Among the product lines, the pants from MoliCare® Mobile and the skincare line MoliCare® Skin enjoyed a growing level of customer acceptance.

Share of total sales by business segment

HARTMANN: Share of total sales by business segment 2017
in EUR million and percent (2018)

Sales within the Wound Management segment rose by 3.6% to €474.2 million, driven by the focus on innovative and high-margin ranges. Here, a two-figure sales plus was recorded by super-absorbent wound dressings and the Hydro Therapy treatment concept. An encouraging rise in sales revenues was also recorded by the Mediset® pre-assembled wound treatment procedure tray.

In 2018, the Infection Management segment achieved growth in sales of 2.6% to €505.5 million, which, among other things, was driven by higher sales volumes for customized surgical procedure trays and specific single-use procedure trays for patient care. The single-use surgical instruments, surgical gloves and Sterillium®Med, a core element of the hand disinfection portfolio, also recorded dynamic growth.

In the Other Group Activities segment, which includes product ranges closely geared towards end-consumers and the retail business, the HARTMANN GROUP increased its sales by 0.7% to €446.2 million. Contributing to this, among other things, was growth from the KNEIPP Group, a leader in the area of bath products that was able to win over customers by continuing its strategy “Kneipp works. Naturally.”

Share of total sales by region

HARTMANN: Share of total sales by region 2017
in EUR million and percent (2018)
Shares of regions in total sales of the HARTMANN GROUP (in million euros and as a percentage; discrepancies due to rounding not adjusted).

We are present in over 35 countries with our own sales and manufacturing organisations, but our solutions are available in around 100 countries through a network of distributors. You can find our offices in a number of countries throughout Europe, but we are also present in America, Africa, Asia, and Oceania.

In Germany, the HARTMANN GROUP includes, among others, the companies BODE Chemie/Hamburg, Karl Otto Braun/Wolfstein, Sanimed/Ibbenbüren and Kneipp/Würzburg.

Performance indicators

With targeted investments in the future and holistic healthcare solutions, we were able to increase Group sales by 2.9% during the 2018 financial year to €2.12 billion. This means we are building on the growth rates of previous years.

At €123.2 million, EBIT has declined over the previous year. This reflects an unfavorable exchange rate development, increasing pressure on prices and margins in the industry, persistently high regulatory costs as well as expenses for sales and infrastructure.

in EUR million 20172018Year-on-year
change
in %
Earnings
Sales revenues2,058.6
2,119.12.9
Of which outside Germany in %66.566.90.6
Consolidated net income93,983.8-10.7
Net return on sales in % 4.64.0-13.0
Cost of materials873,1920,05.4
Personnel expense529,0552,04.3
EBIT DA204,8193,5-5.5
Return on EBIT DA in %9.99.1-8.1
depreciation/amortization on
tangible and intangible assets
62,266,16.3
EBIT138,4123,2-11.0
Return on EBIT in %6.7
5.8-13.4
Cash-Flow169,4156,7-7.4
Free-Cash-Flow-2,5
79,232,68
Balance Sheet
Balance Sheet total1,431,9691,499,3034.6
Non-current assets640,7
645,50,8
Investments in tangible and
intangible assets 2)
197,0
84,9-57.0
Current assets791,5853,87.9
Equity capital and reserves855,0923,18.0
Equity/asset ratio in %59.761.6-3.2
Return on equity in %11.0
9.1
-17.3
Net Financial Status71.7
104.545.8
Employees as at Dec. 31 1)10.76411.0272.4

1) In thousand; excl. staff on parental leave and PAUL HARTMANN AG Management Board members

2) Excluding investments from acquisitions like goodwill